Candidemia in Siriraj hospital: Epidemiology and factors associated with mortality

Journal of the Medical Association of Thailand

Volumn 96, Issue SUPPL2, 2013, Pages

  Boonyasiri, Adhiratha ^a   Jearanaisilavong, Juree ^a   Assanasen, Susan ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Candida albicans; Candidemia; Epidemiology; Inappropriate antifungal therapy; Invasive candidiasis; Non albicans candida; Risk factor

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANDIDA; CANDIDEMIA; DISEASE SEVERITY; DRUG SENSITIVITY; FEMALE; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MORTALITY; NEUTROPENIA; RETROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK;

AGED; CANDIDEMIA; FEMALE; HOSPITALS; HUMANS; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; THAILAND;

EID: 84876019309     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9: 499-511.
2. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642-5.
3. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239-44.
4. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004; 38: 311-20.
5. Wiwattanachang O, Sathapatayavongs B. Candidemia in Ramathibodi hospital: a retrospective study. Rama Med J 1999; 22: 26-34.
6. Tritipwanit K, Chindamporn A, Suankratay C. Epidemiology of candidemia at King Chulalongkorn Memorial Hospital, Thailand. J Infect Dis Antimicrob Agents 2005; 22: 59-69.
7. Diekema DJ, Messer SA, Brueggemann AB, Coffman SL, Doern GV, Herwaldt LA, et al. Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002; 40: 1298-302.
8. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15: 414-21.
9. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37: 1612-8.
10. Anunnatsiri S, Chetchotisakd P, Mootsikapun P. Fungemia in non-HIV-infected patients: a five-year review. Int J Infect Dis 2009; 13: 90-6.
11. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on mortality in cancer patients with candidemia. Antimicrob Agents Chemother 2010; 54: 184-90.
12. Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement, CLSI document M27-S3. Wayne, PA: CLSI; 2012.
13. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
14. Foongladda S, Haouharn P, Sakulmaiwatana P, Chaiprasert A. Comparative evaluation of Candi Select test and conventional methods for identification of Candida albicans in routine clinical isolates. Mycoses 2002; 45: 75-8.
15. Mensa J, Pitart C, Marco F. Treatment of critically ill patients with candidemia. Int J Antimicrob Agents 2008; 32 (Suppl 2): S93-7.
16. Procianoy RS, Silveira RC. Epidemiology of candidemia. J Clin Microbiol 2008; 46: 1894.
17. Bassetti M, Trecarichi EM, Righi E, Sanguinetti M, Bisio F, Posteraro B, et al. Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis 2007; 58: 325-31.
18. DiNubile MJ, Lupinacci RJ, Strohmaier KM, Sable CA, Kartsonis NA. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care 2007; 22: 237-44.
19. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-8.
20. Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999; 29: 1164-70.
21. Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, et al. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). Diagn Microbiol Infect Dis 1999; 35: 19-25.
22. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors or candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001; 33: 177-86.
23. Sandven P, Bevanger L, Digranes A, Gaustad P, Haukland HH, Steinbakk M. Constant low rate of fungemia in norway, 1991 to 1996. The Norwegian Yeast Study Group. J Clin Microbiol 1998; 36: 3455-9.
24. Tortorano AM, Biraghi E, Astolfi A, Ossi C, Tejada M, Farina C, et al. European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region. J Hosp Infect 2002; 51: 297-304.
25. Lamagni TL, Evans BG, Shigematsu M, Johnson EM. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9). Epidemiol Infect 2001; 126: 397-414.
26. Kiertiburanakul S, Areewattananon W, Chongtrakool P, Sutherasan Y, Watcharananan SP. Epidemiology of candidemia and factors associated with candidemia caused by non-albicans candida species: an 8-year experience of a Thai university hospital session [abstracts]. Mycology Friday, October 22, 2010.
27. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998; 31: 327-32.
28. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000; 44: 747-51.
29. Richet H, Roux P, Des CC, Esnault Y, Andremont A. Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect 2002; 8: 405-12.
30. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
31. Girmenia C, Martino P. Fluconazole and the changing epidemiology of candidemia. Clin Infect Dis 1998; 27: 232-4.
32. Chai YA, Wang Y, Khoo AL, Chan FY, Chow C, Kumarasinghe G, et al. Predominance of Candida tropicalis bloodstream infections in a Singapore teaching hospital. Med Mycol 2007; 45: 435-9.
33. Mathews MS, Samuel PR, Suresh M. Emergence of Candida tropicalis as the major cause of fungaemia in India. Mycoses 2001; 44: 278-80.
34. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703.
35. Gudlaugsson O, Gillespie S, Lee K, Vande BJ, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37: 1172-7.
36. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
37. Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, Patel N. The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. Am J Ther 2009; 16: 508-11.
38. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
39. Chaiwarith R, Ounbang P, Khamwan C, Nuntachit N, Sirisanthana T, Supparatpinyo K. Epidemiology of adult candidemia at Chiang Mai University Hospital. Southeast Asian J Trop Med Public Health 2011; 42: 1505-14.
40. Jutiamornlerd N, Chusri S, Siripaitoon P. Epidemiology of candidemia in Songklanagarind Hospital. J Med Assoc Thai 2011; 94: 927-32.